Upstream Bio (UPB) Accounts Payables (2023 - 2026)
Upstream Bio (UPB) posted quarterly Accounts Payables of $1.7 million for Q1 2026, down 63.76% year-over-year from $4.7 million in Q1 2025, and down 37.27% quarter-over-quarter from $2.7 million in Q4 2025.
Upstream Bio (UPB) Accounts Payables (2023 - 2026) Analysis & Trends
Upstream Bio's Accounts Payables history runs 4 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 63.76% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 63.76% YoY), while the FY2025 annual figure was $2.7 million, down 32.54% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.7 million, down from $2.7 million in the prior quarter.
- The five-year high for Accounts Payables was $4.9 million in Q3 2024, with the low at $1.7 million in Q1 2026.
- The 4-year median for Accounts Payables is $3.3 million (2025), against an average of $3.3 million.
- The sharpest annual moves came in 2024 and 2026: Accounts Payables jumped 103.07% in 2024, then slumped 63.76% in 2026.
- Upstream Bio's Accounts Payables stood at $2.0 million in 2023, then soared by 103.07% to $4.0 million in 2024, then plunged by 32.54% to $2.7 million in 2025, then slumped by 37.27% to $1.7 million in 2026.
- Business Quant data shows UPB's Accounts Payables at $1.7 million in Q1 2026, $2.7 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.31 Mn |
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 2.73 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | 4.04 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Dec 31, 2023 | 1.99 Mn |